These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 29186032)
1. In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus. Oh SH; Park HS; Lee JH; Baek SY; Chae SE; Oh K; Cho YL; Kwak JH Molecules; 2017 Nov; 22(12):. PubMed ID: 29186032 [No Abstract] [Full Text] [Related]
2. In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria. Oh SH; Kim J; Baek SY; Chae SE; Park HS; Cho YL; Kwak JH Molecules; 2017 Mar; 22(3):. PubMed ID: 28273820 [TBL] [Abstract][Full Text] [Related]
3. Antibacterial activity of LCB01-0062, a novel oxazolidinone. Jung SJ; Yun IN; Park HS; Lee HH; Jeong JW; Kim YZ; Cho YL; Kwak JH Int J Antimicrob Agents; 2012 Dec; 40(6):539-43. PubMed ID: 23058227 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Jeong JW; Jung SJ; Lee HH; Kim YZ; Park TK; Cho YL; Chae SE; Baek SY; Woo SH; Lee HS; Kwak JH Antimicrob Agents Chemother; 2010 Dec; 54(12):5359-62. PubMed ID: 20855730 [TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Louie A; Liu W; Kulawy R; Drusano GL Antimicrob Agents Chemother; 2011 Jul; 55(7):3453-60. PubMed ID: 21502615 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Shaw KJ; Poppe S; Schaadt R; Brown-Driver V; Finn J; Pillar CM; Shinabarger D; Zurenko G Antimicrob Agents Chemother; 2008 Dec; 52(12):4442-7. PubMed ID: 18838596 [TBL] [Abstract][Full Text] [Related]
7. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686 [TBL] [Abstract][Full Text] [Related]
8. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus. Kim TS; Choe JH; Kim YJ; Yang CS; Kwon HJ; Jeong J; Kim G; Park DE; Jo EK; Cho YL; Jang J Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674049 [No Abstract] [Full Text] [Related]
9. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263 [TBL] [Abstract][Full Text] [Related]
10. TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus. Kaul M; Mark L; Zhang Y; Parhi AK; Lyu YL; Pawlak J; Saravolatz S; Saravolatz LD; Weinstein MP; LaVoie EJ; Pilch DS Antimicrob Agents Chemother; 2015 Aug; 59(8):4845-55. PubMed ID: 26033735 [TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium. Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881 [TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection. Gill CJ; Abruzzo GK; Flattery AM; Misura AS; Bartizal K; Hickey EJ Antimicrob Agents Chemother; 2007 Sep; 51(9):3434-6. PubMed ID: 17606686 [TBL] [Abstract][Full Text] [Related]
15. Resistance to linezolid in a methicillin-susceptible Staphylococcus aureus clinical isolate without previous exposure to oxazolidinones. Quiles-Melero I; García-Perea A; de Pablos M; Gómez-Gil R; Mingorance J Int J Med Microbiol; 2012 Jul; 302(3):145-7. PubMed ID: 22578666 [TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single-Dose Oral LCB01-0371, a Novel Oxazolidinone with Broad-Spectrum Activity, in Healthy Volunteers. Cho YS; Lim HS; Lee SH; Cho YL; Nam HS; Bae KS Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712654 [TBL] [Abstract][Full Text] [Related]
18. In vivo antibacterial activity of MRX-I, a new oxazolidinone. Li CR; Zhai QQ; Wang XK; Hu XX; Li GQ; Zhang WX; Pang J; Lu X; Yuan H; Gordeev MF; Chen LT; Yang XY; You XF Antimicrob Agents Chemother; 2014; 58(4):2418-21. PubMed ID: 24395231 [TBL] [Abstract][Full Text] [Related]
19. Relationship of linezolid minimum inhibitory concentration and time to bacterial eradication in treatment for methicillin-resistant Staphylococcus aureus infection. Moise PA; Castro RS; Sul C; Forrest A; Sakoulas G Ann Pharmacother; 2008 Apr; 42(4):592-3. PubMed ID: 18349303 [No Abstract] [Full Text] [Related]
20. Oxazolidinone-containing Hybrids with Antibacterial Activity against Methicillin-resistant Staphylococcus aureus (MRSA): A Mini-review. Jiang D; Liu B; Gao T Curr Top Med Chem; 2021; 21(27):2440-2454. PubMed ID: 33185161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]